FIGURE 2.

Overall survival of 112 patients with metastatic breast cancer treated with single‐agent pegylated liposomal doxorubicin (PLD) at the University Hospital Basel according to age at the time of treatment initiation (below or above 70 years). Median overall survival was 11.2 months (95% confidence interval 7.9–14.5 months) in patients who were 70 years and older compared to 11.9 months (95% confidence interval 1.0–13.9 months) in patients who were younger than 70 years. p = p‐value, calculated by logrank test.